Quarterly ResultMay 20, 2026, 04:31 PM
Lifeward Q1 Net Loss $10.8M; Going Concern Doubt; Oratech Acquired
AI Summary
Lifeward Ltd. reported a net loss of $10.8 million for the first quarter of 2026, widening from a $4.8 million loss in the prior year. Revenues also declined to $3.9 million from $5.0 million. The company disclosed substantial doubt about its ability to continue as a going concern due to expected operating losses and negative cash flows, despite completing the acquisition of Oratech Pharmaceuticals Ltd. in March 2026 and securing additional financing.
Key Highlights
- Net loss for Q1 2026 was $10.8 million, compared to $4.8 million in Q1 2025.
- Revenues for Q1 2026 decreased to $3.9 million from $5.0 million in Q1 2025.
- Cash and cash equivalents totaled $11.4 million as of March 31, 2026.
- Negative operating cash flow for Q1 2026 was $3.7 million.
- Acquired Oratech Pharmaceuticals Ltd. in March 2026, adding a biomedical pipeline.
- Research and development expenses significantly increased to $5.8 million in Q1 2026.
- Total liabilities increased to $27.1 million from $14.5 million at December 31, 2025.
- A one-for-twelve reverse share split became effective on February 24, 2026.
Price Impact
More from LFWD